Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
Clinical trial NCT07099274 · RECRUITING
Trial details
- NCT number
- NCT07099274
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-22
- Primary completion
- 2027-12-30
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.